Tenpoint Therapeutics

Tenpoint's lead program is BRIMOCHOL PF, a topical drop intended to improve near vision by restoring lens elasticity — a mechanism distinct from the pupil-constricting miotic agents that dominated earlier presbyopia pipelines. Miotics improve depth of focus by creating a pinhole effect; Tenpoint's approach targets the lens directly. The firm believes this may produce a better tolerability profile and longer duration of effect for daily use.

Henric Bjarke serves as CEO and sits on the board. Ben Bergo is President and Chief Business Officer, a role that typically oversees financing, partnerships, and corporate strategy. The board includes Chairman David Guyer, MD, and directors from venture and ophthalmic-medicine backgrounds, though Tenpoint has not publicly disclosed which entity leads its investment committee or capital-allocation decisions.

Tenpoint markets itself as an integrated eye-care company — it is building its own commercial team under Chief Commercial Officer Carol Kearney rather than seeking an approval-and-partner pathway. This ambition places it between a development-stage biotech and a specialty-pharma operating company, with the attendant capital requirements. No disclosed funding rounds or revenue yet confirm its balance-sheet capacity to launch at scale.

The firm's pipeline includes programs for early cataract — aiming to restore lens clarity pharmacologically — and a cell-therapy program for geographic atrophy, the advanced form of dry age-related macular degeneration. Tenpoint frames these as a continuum of lens and retinal rejuvenation, though no clinical data or trial identifiers are publicly disclosed beyond the presbyopia NDA.

The firm's website indicates a direct-to-eye-care-professional model, with US regulatory activity (FDA acceptance of the BRIMOCHOL PF NDA) suggesting the first commercial target is the American presbyopia market. Tenpoint has not disclosed regional partnership agreements or ex-US commercial plans, though the Cambridge HQ may anchor European clinical or regulatory operations.

The board and management team bring extensive ophthalmology-industry ties. Chairman David Guyer, MD, co-founded Eyetech Pharmaceuticals and served as CEO; board member Eric Donnenfeld, MD, is a prominent corneal surgeon and ophthalmic-company advisor; and Jim Mazzo, a director, previously led Advanced Medical Optics and AcuFocus. These relationships could inform Tenpoint's commercial strategy and clinical-advisory reach.

No institutional investor or venture-backing disclosures appear on the firm's website or in its public materials as of mid-2026. The composition of the board — which includes directors with venture and industry-operating backgrounds — implies equity backing, but Tenpoint has not named a lead investor, disclosed a funding round, or published a capitalization table.